Tseng, Vincent W.-S. http://orcid.org/0000-0002-4824-0615
Sano, Akane
Ben-Zeev, Dror
Brian, Rachel
Campbell, Andrew T.
Hauser, Marta
Kane, John M.
Scherer, Emily A.
Wang, Rui
Wang, Weichen
Wen, Hongyi
Choudhury, Tanzeem
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH103148)
Article History
Received: 28 January 2019
Accepted: 11 August 2020
First Online: 15 September 2020
Competing interests
: D.B. has consulted for Equity and has had an intervention content licensing agreement with Pear Therapeutics. J.K. has been a consultant for or received honoraria from Alkermes, Forest (Allergan), Genentech, H. Lundbeck. Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, Merck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda and Teva. J.K. has participated in Advisory Boards for Alkermes, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, Teva. J.K. has received grant support from Otsuka, Lundbeck and Janssen. J.K. is a Shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. T.C. is the CEO of HealthRhythms. A.S. has received travel reimbursement or honorarium payments from Philips Research, Apple, Gordon Research Conferences, Pola Chemical Industries, Leuven Mindgate, American Epilepsy Society, and IEEE. The authors declare no competing interests.